Ultragenyx Pharmaceutical Inc (RARE)
42.61
+1.49
(+3.62%)
USD |
NASDAQ |
May 16, 16:00
42.60
-0.01
(-0.02%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Free Cash Flow: -543.61M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
March 31, 2024 | -543.61M |
December 31, 2023 | -521.57M |
September 30, 2023 | -553.38M |
June 30, 2023 | -553.20M |
March 31, 2023 | -528.78M |
December 31, 2022 | -526.59M |
September 30, 2022 | -479.67M |
June 30, 2022 | -438.49M |
March 31, 2022 | -415.73M |
December 31, 2021 | -411.79M |
September 30, 2021 | -425.79M |
June 30, 2021 | -411.33M |
March 31, 2021 | -242.64M |
December 31, 2020 | -176.12M |
September 30, 2020 | -175.27M |
June 30, 2020 | -203.06M |
March 31, 2020 | -380.63M |
December 31, 2019 | -370.22M |
September 30, 2019 | -343.72M |
June 30, 2019 | -320.37M |
March 31, 2019 | -303.52M |
Date | Value |
---|---|
December 31, 2018 | -294.64M |
September 30, 2018 | -320.32M |
June 30, 2018 | -313.16M |
March 31, 2018 | -284.90M |
December 31, 2017 | -256.64M |
September 30, 2017 | -222.26M |
June 30, 2017 | -190.98M |
March 31, 2017 | -186.48M |
December 31, 2016 | -171.16M |
September 30, 2016 | -165.18M |
June 30, 2016 | -166.02M |
March 31, 2016 | -139.19M |
December 31, 2015 | -110.93M |
September 30, 2015 | -81.47M |
June 30, 2015 | -60.36M |
March 31, 2015 | -53.71M |
December 31, 2014 | -46.78M |
September 30, 2014 | -43.78M |
June 30, 2014 | -39.26M |
March 31, 2014 | -36.33M |
December 31, 2013 | -31.61M |
Free Cash Flow Range, Past 5 Years
-553.38M
Minimum
Sep 2023
-175.27M
Maximum
Sep 2020
-401.10M
Average
-413.76M
Median
Free Cash Flow Benchmarks
Corcept Therapeutics Inc | 124.84M |
Madrigal Pharmaceuticals Inc | -391.12M |
Sarepta Therapeutics Inc | -653.88M |
FibroGen Inc | -274.68M |
Rocket Pharmaceuticals Inc | -209.70M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | -190.73M |
Cash from Investing (Quarterly) | 94.44M |
Cash from Financing (Quarterly) | -0.058M |
Free Cash Flow Per Share (Quarterly) | -2.420 |
Free Cash Flow to Equity (Quarterly) | -203.94M |
Free Cash Flow to Firm (Quarterly) | -196.90M |
Free Cash Flow Yield | -16.57% |